[Skip to Content]
[Skip to Content Landing]
Citations 0
February 14, 2007

Cyclooxygenase Inhibitors and Cardiovascular Risk—Reply

Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2007;297(6):586-588. doi:10.1001/jama.297.6.587

In Reply: Dr Andersohn and colleagues suggest that the highest risks of cardiovascular events with celecoxib are seen in European study populations, where the CYP2C9*3 allele associated with slow metabolism of celecoxib (and by implication an increased risk of thrombosis) may occur with a frequency of as much as 16%. This is an interesting suggestion, but we can speculate that it may not be the most likely explanation for the heterogeneity observed in the study results.

First Page Preview View Large
First page PDF preview
First page PDF preview